Recombinant proteins | Insulin-like Growth Factor 1 | Stroke Treatment Agent
Stroke Treatment Agent
A hybrid protein based on IGF-1 has been developed, exhibiting prolonged neuroprotective activity. The drug is designed for stroke treatment via intranasal administration, ensuring direct delivery of the active substance to the brain. This method extends its protective effect on neurons and reduces the consequences of ischemic damage.

Key Features of the Method:

• Optimal timing: Administration as early as possible after stroke onset
• Delivery route: Intranasal (through the nose), enabling rapid brain uptake

Additional Application Opportunities:

• Treatment and prevention of other conditions requiring neuroprotection
• Therapy for disorders benefiting from IGF-1 activity (e.g., neurodegenerative diseases, brain injuries).

Advantages of the Approach:

• Extended duration of action → Reduced dosing frequency
• Non-invasive delivery → Enhanced safety and convenience
• Broad therapeutic potential due to IGF-1's mechanism of action